These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. Leuzy A; Zimmer ER; Heurling K; Rosa-Neto P; Gauthier S Amyloid; 2014 Sep; 21(3):143-8. PubMed ID: 24919109 [TBL] [Abstract][Full Text] [Related]
27. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949 [TBL] [Abstract][Full Text] [Related]
28. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008 [TBL] [Abstract][Full Text] [Related]
29. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]
30. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Salazar J; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ; Alzheimers Dement; 2017 May; 13(5):561-571. PubMed ID: 27931796 [TBL] [Abstract][Full Text] [Related]
33. Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition. Tolbert S; Liu Y; Hellegers C; Petrella JR; Weiner MW; Wong TZ; Murali Doraiswamy P J Prev Alzheimers Dis; 2019; 6(4):274-282. PubMed ID: 31686100 [TBL] [Abstract][Full Text] [Related]
34. Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative. Groechel RC; Tripodis Y; Alosco ML; Mez J; Qiu WQ; Mercier G; Goldstein L; Budson AE; Kowall NW; Killiany RJ; Neurobiol Aging; 2023 Jul; 127():33-42. PubMed ID: 37043881 [TBL] [Abstract][Full Text] [Related]
35. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833 [TBL] [Abstract][Full Text] [Related]
36. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW; Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191 [TBL] [Abstract][Full Text] [Related]
37. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060 [TBL] [Abstract][Full Text] [Related]
38. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW; Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697 [TBL] [Abstract][Full Text] [Related]
39. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Rueda AD; Lau KM; Saito N; Harvey D; Risacher SL; Aisen PS; Petersen RC; Saykin AJ; Farias ST; Alzheimers Dement; 2015 Sep; 11(9):1080-9. PubMed ID: 25449531 [TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]